Thompson称：卫生福利部与拜耳公司就Cipro的价格进
WASHINGTON (Reuters Health) - Secretary of Health and Human Services (HHS) Tommy Thompson told lawmakers on Tuesday that the government is negotiating with Bayer over pricing for the anthrax-fighting antibiotic Cipro (ciprofloxacin).
"I made crystal-clear to Bayer that we will not accept the price they offered and we will be negotiating this afternoon," Thompson told the House Committee on Government Reform's subcommittee on National Security, Veterans' Affairs and International Relations. HHS plans to purchase large amounts of Cipro to add to its stockpile of drugs to combat bioterrorism.
Thompson said the government lacks the authority to override Bayer's patent protection on the drug to approve and purchase generic versions--but he stressed that the US government will demand reasonable pricing for the massive order it is placing.
House lawmakers supported an aggressive stance in the discussions with Bayer. "It is incumbent upon our government to tell the pharmaceutical industry that they can forget about their profits, that we need that product...at a cost that is affordable to individuals and to the United States government," said Rep. Bernard Sanders, I-VT., 百拇医药
"I made crystal-clear to Bayer that we will not accept the price they offered and we will be negotiating this afternoon," Thompson told the House Committee on Government Reform's subcommittee on National Security, Veterans' Affairs and International Relations. HHS plans to purchase large amounts of Cipro to add to its stockpile of drugs to combat bioterrorism.
Thompson said the government lacks the authority to override Bayer's patent protection on the drug to approve and purchase generic versions--but he stressed that the US government will demand reasonable pricing for the massive order it is placing.
House lawmakers supported an aggressive stance in the discussions with Bayer. "It is incumbent upon our government to tell the pharmaceutical industry that they can forget about their profits, that we need that product...at a cost that is affordable to individuals and to the United States government," said Rep. Bernard Sanders, I-VT., 百拇医药
参见：首页 > 医疗版 > 疾病专题 > 耳鼻喉科 > 耳疾病 > 概述